Objective: This study aimed to evaluate the usability of size and volume of lymph nodes (LNs) in the pelvis and lower abdomen to predict metastatic disease in patients with carcinoma of the urinary bladder.

Material And Methods: LNs retrieved from 177 patients undergoing radical cystectomy and extended LN dissection were prospectively registered with number, location, presence of metastatic disease, longitudinal length, transverse diameter and a calculated LN volume.

Results: A mean of 21.2 LNs was removed from each patient. Thirty-eight patients (21.5%) had positive LNs. The total LN volume per patient was independent of the number of LNs removed, whereas mean volume per LN was inversely proportional to the number of LNs removed in node-negative patients, suggesting a physiological variation in the number of pelvic LNs. Positive LNs were generally larger than negative LNs. This difference was more pronounced using the transverse diameter than using longitudinal length. Calculated higher volume of an LN was also associated with an increased risk of metastases. However, no optimal cut-off values predicting metastatic disease based on LN size were found owing to low sensitivity and low predictive value at the tested cut-off values. The size difference comparing positive and negative LNs was therefore not clinically applicable as an overall preoperative risk estimation of metastatic disease.

Conclusions: A fixed volume of lymphatic tissue rather than a fixed number of LNs seems to be present in node-negative patients. Size of LNs remains a poor predictor of metastatic disease in bladder cancer.

Download full-text PDF

Source
http://dx.doi.org/10.3109/00365591003796432DOI Listing

Publication Analysis

Top Keywords

metastatic disease
16
lns
12
lns removed
12
number lns
12
size volume
8
lymph nodes
8
pelvis lower
8
lower abdomen
8
patients carcinoma
8
undergoing radical
8

Similar Publications

Purpose: To present the case of a young patient with BRAF V600E-mutant cutaneous melanoma who developed bilateral choroidal metastases complicated by neovascular glaucoma (NVG) in both eyes following the interruption of nivolumab therapy.

Methods: A 28-year-old female with primary cutaneous melanoma of the left hand underwent surgical resection and adjuvant nivolumab. Immunotherapy was discontinued due to immune-related acute interstitial nephritis.

View Article and Find Full Text PDF

Update on the Progress of Musashi-2 in Malignant Tumors.

Front Biosci (Landmark Ed)

January 2025

Department of Hepatobiliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032 Taiyuan, Shanxi, China.

Since the discovery of the Musashi (MSI) protein, its ability to affect the mitosis of Drosophila progenitor cells has garnered significant interest among scientists. In the following 20 years, it has lived up to expectations. A substantial body of evidence has demonstrated that it is closely related to the development, metastasis, migration, and drug resistance of malignant tumors.

View Article and Find Full Text PDF

Introduction: Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP-ribose) polymerase inhibitors. We analyzed real-world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring germline BRCA mutations in Italy, where olaparib is not reimbursed for this indication.

Methods: Clinico/pathological data of pancreatic cancer patients with documented BRCA1-2 germline pathogenic variants who had received first-line chemotherapy for metastatic disease were collected from 23 Italian oncology departments and the impact of olaparib exposure on overall survival (OS) was analyzed.

View Article and Find Full Text PDF

Chordomas are a low-to-intermediate-grade slow-growing subtype of sarcoma, but show propensity to grow and invade locally with recurrence and metastasis in 10-40% of cases. We describe the first case of spontaneous regression of a solid tumor (histologically and immunohistochemically proven chordoma) after COVID-19. A female patient with clival chordoma underwent occipitocervical fixation prior to tumor resection.

View Article and Find Full Text PDF

Post-translational modifications (PTMs) of proteins dynamically build the buffering and adapting interface between oncogenic mutations and environmental stressors, on the one hand, and cancer cell structure, functioning, and behavior. Aberrant PTMs can be considered as enabling characteristics of cancer as long as they orchestrate all malignant modifications and variability in the proteome of cancer cells, cancer-associated cells, and tumor microenvironment (TME). On the other hand, PTMs of proteins can enhance anticancer mechanisms in the tumoral ecosystem or sustain the beneficial effects of oncologic therapies through degradation or inactivation of carcinogenic proteins or/and activation of tumor-suppressor proteins.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!